Partial E3 Adenoviral Vectors for Toxic Transgene Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing adenoviral vectors used in vaccine development and gene therapy face instability due to the expression of toxic antigenic proteins, leading to vector degradation and inefficiency.
Innovation Solution
Development of replication-incompetent adenoviral vectors with selective deletions in the E3 region, retaining anti-apoptotic functions, either by partial E3 retention or inclusion of anti-apoptotic proteins, to stabilize the vector and enable expression of toxic proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adenoviral vectors express toxic antigenic proteins, then immune response is enhanced, but vector stability deteriorates
Solution Approach 1:
The patent extracts and removes the E3 region from the adenoviral vector genome, which contains genes encoding toxic proteins. By deleting this specific region while retaining essential anti-apoptotic functions through alternative means (E3* region or external expression), the vector eliminates self-toxicity and stabilizes the system without compromising immune response capability
Solution Approach 2:
The patent introduces an intermediary E3* region or external anti-apoptotic protein expression as a mediator that compensates for the loss of E3 region. This intermediary provides the necessary anti-apoptotic function to maintain vector stability while allowing the expression of toxic antigenic proteins without triggering cell death
2Productivity
If adenoviral vectors undergo multiple passages, then productivity increases, but vector integrity deteriorates
Solution Approach 1:
By removing the E3 region that contains genes responsible for vector degradation and instability during propagation, the patent enables vectors to undergo multiple passages without losing integrity. The extraction of problematic genomic elements allows sustained productivity across passages
Solution Approach 2:
The patent changes the genomic composition parameter by deleting the E3 region and introducing compensatory anti-apoptotic mechanisms. This parameter change allows the vector to maintain stability and integrity during multiple passages, enabling extended propagation without degradation
Data Source
AI summary
This disclosure provides replication-incompetent adenoviral vectors useful in vaccine development and gene therapy. The disclosed vectors comprise a selective deletion of E3 and are particularly useful for preparation of vaccines development and for gene therapy using toxic transgene products that result in vector instability that occurs when the entire E3 domain is deleted.